Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Voyager Acquisition Corp./Cayman Islands amended Second Amendment and Waiver with Veraxa Biotech AG and Oliver Baumann valued at $1,350,000,000 (effective 2026-02-02).
- Action
- amendment
- Agreement
- merger
- Counterparty
- Veraxa Biotech AG and Oliver Baumann
- Value
- $1,350,000,000
- Effective
- 2026-02-02
Exact text from the filing
On February 2, 2026, Voyager Acquisition Corp. (the “ Company ”) entered into that certain Second Amendment and Waiver (the “ Amendment ”) to that certain Business Combination Agreement dated as of April 22, 2025 as amended on October 18, 2025 (the “ BCA ”), by and among the Company, Veraxa Biotech AG (“ Veraxa ”), and Oliver Baumann, in his capacity as representative for the shareholders of Veraxa.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Voyager Acquisition Corp./Cayman Islands amended First Amendment to Sponsor Support Agreement with Veraxa and Voyager Acquisition Sponsor Holdco LLC (effective 2026-02-02).
- Action
- amendment
- Counterparty
- Veraxa and Voyager Acquisition Sponsor Holdco LLC
- Effective
- 2026-02-02
Exact text from the filing
On February 2, 2026, Veraxa and Voyager Acquisition Sponsor Holdco LLC (the “ Sponsor ”) entered into that certain First Amendment to Sponsor Support Agreement, amending that certain Sponsor Support Agreement dated as of April 22, 2025 (the “ Sponsor Support Agreement ”), between the Company, Veraxa and the Sponsor, pursuant to which the Sponsor agreed, in connection with the Closing (as defined in the BCA), to forfeit for cancellation for no consideration 200,000 Class B Ordinary Shares (as defined in the BCA) and 400,000 SPAC Warrants (as defined in the BCA) for which a corresponding number of PubCo Ordinary Shares (as defined therein) and PubCo Warrants (as defined in the BCA) will be issued to shareholders of Veraxa.
View on SEC.gov